脑透补充抑制在阿尔茨海默病小鼠模型中减轻神经退行
Wioleta M Zelek1, Ryan J Bevan1, Jacqui Nimmo1
1School of Medicine, UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF14 4XN, UK.
Brain : a journal of neurology
|August 31, 2024
概括
一种针对大脑炎症的新型抗体减少了阿尔茨海默病的病理学,并改善了小鼠的认知能力. 这种穿透大脑的疗法通过阻断补体激活来治疗神经退行性疾病具有前景.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 补充激活有助于在阿尔茨海默氏症 (AD) 中的大脑炎症和神经退行.
- 准补充系统是阿尔茨海默病的潜在治疗策略.
研究的目的:
- 在AD小鼠模型中研究向膜攻击复合体 (MAC) 的脑透抗体的疗效.
- 评估抗体对神经炎症,粉样蛋白病理,突触损失和认知功能的影响.
主要方法:
- 设计了一种重组,穿透大脑的抗体来对抗促炎性MAC.
- 对APPNL-G-F小鼠 (一种AD模型) 系统地注射抗体.
- 测量了补充激活产品,突触完整性,粉样蛋白负担,炎症性细胞因子和认知表现.
主要成果:
- 抗体成功进入大脑并与其目标接触,减少补充激活产品.
- 长期治疗导致突触损失,粉样蛋白负担和脑炎症细胞因子水平的降低.
- 与对照组相比,在接受治疗的小鼠中,认知功能显著改善.
结论:
- 脑透补充抑制是阿尔茨海默病的可行的治疗方法.
- 针对粉样质斑块的下游,特别是补充级联,为AD治疗提供了一个有希望的策略.
相关概念视频
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170